MX2019009986A - Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. - Google Patents
Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias.Info
- Publication number
- MX2019009986A MX2019009986A MX2019009986A MX2019009986A MX2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative
- cell activation
- early detection
- glial cell
- neuroinflammatory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Abstract
La descripcion proporciona un metodo para determinar la eficacia del tratamiento con un antagonista de SEMA4D, por ejemplo, un anticuerpo antagonista de SEMA4D en el tratamiento de una enfermedad, trastorno o lesion neuroinflamatoria o neurodegenerativa, donde el metodo proporciona una medicion diferencial de la captacion de glucosa en el cerebro, por ejemplo, mediante imagenes de FDG-PET.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762461945P | 2017-02-22 | 2017-02-22 | |
PCT/US2018/018794 WO2018156509A1 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019009986A true MX2019009986A (es) | 2019-10-14 |
Family
ID=63253999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019009986A MX2019009986A (es) | 2017-02-22 | 2018-02-20 | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190383836A1 (es) |
EP (1) | EP3585435A4 (es) |
JP (1) | JP2020510845A (es) |
KR (1) | KR102533921B1 (es) |
CN (1) | CN110325213A (es) |
AU (1) | AU2018225493A1 (es) |
BR (1) | BR112019017367A2 (es) |
CA (1) | CA3050328A1 (es) |
IL (1) | IL267940A (es) |
MX (1) | MX2019009986A (es) |
RU (1) | RU2766341C2 (es) |
SG (1) | SG11201906670PA (es) |
WO (1) | WO2018156509A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ618067A (en) | 2009-05-08 | 2015-07-31 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
CA3098741A1 (en) | 2013-06-25 | 2014-12-31 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
MX2019001453A (es) | 2016-08-02 | 2019-06-20 | Vaccinex Inc | Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas. |
EP4172205A1 (en) | 2020-06-25 | 2023-05-03 | Vaccinex, Inc. | Use of semaphorin-4d binding molecules for the treatment of rett syndrome |
CA3231551A1 (en) * | 2021-09-27 | 2023-03-30 | Maurice Zauderer | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
NZ588713A (en) * | 2008-05-09 | 2012-10-26 | Abbott Gmbh & Co Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
SG11201401458UA (en) * | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2018
- 2018-02-20 CN CN201880013208.3A patent/CN110325213A/zh active Pending
- 2018-02-20 BR BR112019017367A patent/BR112019017367A2/pt unknown
- 2018-02-20 MX MX2019009986A patent/MX2019009986A/es unknown
- 2018-02-20 SG SG11201906670PA patent/SG11201906670PA/en unknown
- 2018-02-20 US US16/488,123 patent/US20190383836A1/en active Pending
- 2018-02-20 CA CA3050328A patent/CA3050328A1/en active Pending
- 2018-02-20 JP JP2019566047A patent/JP2020510845A/ja active Pending
- 2018-02-20 EP EP18757318.3A patent/EP3585435A4/en active Pending
- 2018-02-20 KR KR1020197027287A patent/KR102533921B1/ko active IP Right Grant
- 2018-02-20 WO PCT/US2018/018794 patent/WO2018156509A1/en unknown
- 2018-02-20 AU AU2018225493A patent/AU2018225493A1/en active Pending
- 2018-02-20 RU RU2019122337A patent/RU2766341C2/ru active
-
2019
- 2019-07-09 IL IL267940A patent/IL267940A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201906670PA (en) | 2019-08-27 |
RU2766341C2 (ru) | 2022-03-15 |
IL267940A (en) | 2019-09-26 |
AU2018225493A1 (en) | 2019-08-01 |
WO2018156509A1 (en) | 2018-08-30 |
KR102533921B1 (ko) | 2023-05-17 |
EP3585435A4 (en) | 2020-12-16 |
RU2019122337A3 (es) | 2021-06-09 |
KR20190120784A (ko) | 2019-10-24 |
JP2020510845A (ja) | 2020-04-09 |
RU2019122337A (ru) | 2021-03-23 |
BR112019017367A2 (pt) | 2020-04-14 |
EP3585435A1 (en) | 2020-01-01 |
CA3050328A1 (en) | 2018-08-30 |
US20190383836A1 (en) | 2019-12-19 |
CN110325213A (zh) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019009986A (es) | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. | |
PH12019501146A1 (en) | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging | |
CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
MX2016011155A (es) | Anticuerpo que une erbb-2 y erbb-3. | |
WO2012054639A3 (en) | Nmr systems and methods for the rapid detection of analytes | |
EP3587597C0 (en) | METHOD FOR DIAGNOSING PARKINSON'S DISEASE BY BACTERIAL METAGENOME ANALYSIS | |
MA43151A (fr) | Anticorps monoclonaux spécifiques pour le sérogroupe x de n. meningitidis et leurs utilisations dans le diagnostic | |
EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
NZ707116A (en) | Ly75 as cancer therapeutic and diagnostic target | |
EP4273551A3 (en) | Multiplexed total antibody and antibody-conjugated drug quantification assay | |
MX2021003764A (es) | Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia. | |
IL263024A (en) | Blood sample analysis method and system, for determining diabetes | |
PH12019501837A1 (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
MX2021009528A (es) | Prueba de diagnostico basada en fragmento de rgma. | |
WO2016014799A9 (en) | Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy | |
EP3487524A4 (en) | HUMANIZED ANTI-TAU ANTIBODIES, COMPOSITIONS AND MANUFACTURING METHODS AND METHODS OF USE IN THE TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES | |
FR3037147B1 (fr) | Procede et dispositif de reflectometrie pour le diagnostic de cables en fonctionnement. | |
SG10201806729VA (en) | Novel assay to detect human periostin | |
BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer | |
EP4283304A3 (en) | Methods of detecting anti-leptin neutralizing antibodies | |
EP3604550A4 (en) | ATP DETECTION PROCESS USING AN INDIVIDUAL GLYCOMETER | |
WO2014169011A3 (en) | Methods for treating immune diseases | |
BR112019006422A2 (pt) | anticorpo monoclonal contra fzd10 e utilização do mesmo | |
IL272484A (en) | Systems and methods for improving disease diagnosis using measured test substances |